New Novozymes exec to halt bleeding in struggling growth division

A priority for Novozymes Executive Vice President Tine Sejersgård Fanø is to halt the bleeding which has rendered the growth field of bioethanol a deep disappointment.
Photo: Novozymes/ PR
Photo: Novozymes/ PR
BY FINANS

2017 will be a fateful year for Novozymes, with critical focus on restoring investor confidence in the company.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading

Jobs

See all jobs